INTRODUCTION Approximately 25% of HF patients overall and 40% of hospitalized HF patients have DM [3,4,18]
Set up manually: Episode Notes On todays episode, hosts Candice Lim and Kate Lindsay are joined by writer Virgie Tovar, whose latest podcast, GLP-1 Truth Serum, explores the predatory nature of GLP-1 marketing, and companies attempts to target plus-size creators
If protein intake was too low, strength training was minimal, or muscle mass declined, the metabolic foundation remains fragile once medication support is removed
Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3) GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice
In these STEP trials, most participants experienced mild to moderate symptoms, with the incidence of severe side effects being 9.8% in the semaglutide treatment group and 6.4% in the placebo group
Following GLP-1 deprescription, patients weight did not significantly increase at 6 or 12 months post deprescription, compared to many well-known drug trials (in red) where patients regain up to two thirds of weight loss after discontinuing the drug